Metabolic profiling of the impact of oligofructose-enriched inulin in Crohn's disease patients: A double-blinded randomized controlled trial

Clinical and Translational Gastroenterology

Volumn 4, Issue , 2013, Pages

  De Preter, Vicky ^a   Joossens, Marie ^a,b,c   Ballet, Vera ^a   Shkedy, Ziv ^d   Rutgeerts, Paul ^a   Vermeire, Severine ^a   Verbeke, Kristin ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^d HASSELT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACETALDEHYDE; BUTYRIC ACID; CARBOHYDRATE; HEPTANOATE; HEXANOIC ACID; INULIN; MALTODEXTRIN; MEDIUM CHAIN FATTY ACID; OLIGOFRUCTOSE ENRICHED INULIN; PARA CRESOL; PENTANOATE; PLACEBO; PREBIOTIC AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; COLON FLORA; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; FECES ANALYSIS; FEMALE; FERMENTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS FRAGMENTOGRAPHY; METABOLITE; METABOLOME; MICROBIAL ACTIVITY; MICROBIAL COMMUNITY; MICROBIAL METABOLISM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

EID: 84887005566     PISSN: None     EISSN: 2155384X     Source Type: Journal    
DOI: 10.1038/ctg.2012.24     Document Type: Article

References (47)

1. Rutgeerts P, Geboes K, Peeters M et al. Effect of fecal stream diversion on recurrence of crohns-disease in the neoterminal ileum. Lancet 1991; 338: 771-774.
2. Seksik P, Sokol H, Lepage P et al. Review article: the role of bacteria in onset and perpetuation of inflammatory bowel disease. Aliment Pharmacol Ther 2006; 24: 11-18. (Pubitemid 44326413)
3. Sokol H, Pigneur B, Watterlot L et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 2008; 105: 16731-16736.
4. Sokol H, Seksik P, Rigottier-Gois L et al. Specificities of the fecal microbiota in inflammatory bowel disease. Inflamm Bowel Dis 2006; 12: 106-111.
5. Tamboli CP, Neut C, Desreumaux P et al. Dysbiosis in inflammatory bowel disease. Gut 2004; 53: 1-4. (Pubitemid 38082999)
6. Favier C, Neut C, Mizon C et al. Fecal beta-D-galactosidase production and Bifidobacteria are decreased in Crohn's disease. Dig Dis Sci 1997; 42: 817-822. (Pubitemid 27196036)
7. Seksik P, Rigottier-Gois L, Gramet G et al. Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon. Gut 2003; 52: 237-242. (Pubitemid 36115065)
8. Swidsinski A, Ladhoff A, Pernthaler A et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002; 122: 44-54. (Pubitemid 34049193)
9. Frank DN St, Amand AL, Feldman RA et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA 2007; 104: 13780-13785. (Pubitemid 350003397)
10. Willing B, Halfvarson J, Dicksved J et al. Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn's disease. Inflamm Bowel Dis 2009; 15: 653-660.
11. Joossens M, Huys G, Cnockaert M et al. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut 2011; 60: 631-637.
12. Delzenne NM, Williams CM. Prebiotics and lipid metabolism. Curr Opin Lipidol 2002; 13: 61-67. (Pubitemid 34174630)
13. Roberfroid MB. Introducing inulin-type fructans. Br J Nutr 2006; 93: S13-S25. (Pubitemid 43073402)
14. Gibson GR, Probert HM, Van Loo J et al. Dietary modulation of the human colonic microbiota: updating the concept of prebiotics. Nutr Res Rev 2004; 17: 259-275.
15. De Preter V, Vanhoutte T, Huys G et al. Baseline microbiota activity and influence responses to prebiotic initial bifidobacteria counts dosing in healthy subjects. Aliment Pharmacol Ther 2008; 27: 504-513. (Pubitemid 351300850)
16. Kolida S, Tuohy K, Gibson GR. Prebiotic effects of inulin and oligofructose. Br J Nutr 2002; 87: S193-S197. (Pubitemid 34685554)
17. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004; 126: 1620-1633. (Pubitemid 38649878)
18. Joossens M, De Preter V, Ballet V et al. Effect of oligofructose-enriched inulin (OF-IN) on bacterial composition and disease activity of patients with Crohn's disease: results from a double-blinded randomised controlled trial. Gut 2012; 61: 958.
19. Benjamin JL, Hedin CR, Koutsoumpas A et al. Randomised, double-blind, placebocontrolled trial of fructo-oligosaccharides in active Crohn's disease. Gut 2011; 60: 923-929.
20. Zoetendal EG, Rajilic-Stojanovic M, de Vos WM. High-throughput diversity and functionality analysis of the gastrointestinal tract microbiota. Gut 2008; 57: 1605-1615.
21. Nicholson JK, Lindon JC, Holmes E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999; 29: 1181-1189.
22. Marchesi JR, Holmes E, Khan F et al. Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J Proteome Res 2007; 6: 546-551. (Pubitemid 46340158)
23. Jansson J, Willing B, Lucio M et al. Metabolomics reveals metabolic biomarkers of Crohn's disease. PLoS One 2009; 4: e6386.
24. Williams HR, Cox IJ, Walker DG et al. Characterization of inflammatory bowel disease with urinary metabolic profiling. Am J Gastroenterol 2009; 104: 1435-1444.
25. Vermeire S, Schreiber S, Sandborn WJ et al. Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity. Clin Gastroenterol Hepatol 2010; 8: 357-363.
26. Meijers BK, De Preter V, Verbeke K et al. p-Cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin. Nephrol Dial Transplant 2009; 25: 219-224.
27. Jenkins DJA, Kendall CWC, V Vuksan. Inulin oligofructose and intestinal function. J Nutr 1999; 129: 1431S-1433SS.
28. De Preter V, Van Staeyen G, Esser D et al. Development of a screening method to determine the pattern of fermentation metabolites in faecal samples using on-line purgeand-trap gas chromatographic-mass spectrometric analysis. J Chromatogr A 2009; 1216: 1476-1483.
29. Joossens M, Huys G, Van Steen K et al. High-throughput method for comparative analysis of denaturing gradient gel electrophoresis profiles from human fecal samples reveals significant increases in two bifidobacterial species after inulin-type prebiotic intake. FEMS Microbiol Ecol 2011; 75: 343-349.
30. De Preter V, Ghebretinsae AH, Abrahantes JC et al. Impact of the synbiotic combination of Lactobacillus casei shirota and oligofructose-enriched inulin on the fecal volatile metabolite profile in healthy subjects. Mol Nutr Food Res 2011; 55: 714-722.
31. Benjamini Y, Hochberg Y. Controlling the false discovery rate - a practical and powerful approach to multiple testing. J Royal Stat Soc S B Methodolo 1995; 57: 289-300.
32. Korpi A, Järnberg J, Pasanen A. Microbial volatile organic compounds (MVOC). In: Marklund S, Christmansson M, Holmberg K et al. (eds). National Institute for Working Life: Stockholm, Sweden, 2007 1-78.
33. Roediger WEW. Role of anaerobic-bacteria in the metabolic welfare of the colonic mucosa in man. Gut 1980; 21: 793-798. (Pubitemid 11209227)
34. Hamer HM, Jonkers D, Venema K et al. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther 2008; 27: 104-119. (Pubitemid 350256609)
35. Place RF, Noonan EJ, Giardina C. HDAC inhibition prevents NF-kappa B activation by suppressing proteasome activity: down-regulation of proteasome subunit expression stabilizes I kappa B alpha. Biochem Pharmacol 2005; 70: 394-406. (Pubitemid 40905111)
36. De Preter V, Hamer HM, Windey K et al. The impact of pre- and/or probiotics on human colonic metabolism: does it affect human health? Mol Nutr Food Res 2011; 55: 46-57.
37. Falony G, Verschaeren A, De Bruycker F et al. In vitro kinetics of prebiotic inulin-type fructan fermentation by butyrate-producing colon bacteria: implementation of online gas chromatography for quantitative analysis of carbon dioxide and hydrogen gas production. Appl Environ Microbiol 2009; 75: 5884-5892.
38. De Lacy Costello B, Ewen R, Ewer AK et al. An analysis of volatiles in the headspace of the faeces of neonates. J Breath Res 2008; 2: 037023.
39. Salaspuro MP. Acetaldehyde, microbes, and cancer of the digestive tract. Crit Rev Clin Lab Sci 2003; 40: 183-208. (Pubitemid 36529014)
40. Zidi SH, Linderborg K, Vakevainen S et al. Lactulose reduces intracolonic acetaldehyde concentration and ethanol elimination rate in rats. Alcohol Clin Exp Res 2003; 27: 1459-1462. (Pubitemid 37151476)
41. Kayani MA, Parry JM. The in vitro genotoxicity of ethanol and acetaldehyde. Toxicol In Vitro 2010; 24: 56-60.
42. Jorgensen JR, Clausen MR, Mortensen PB. Oxidation of short and medium chain C2-C8 fatty acids in Sprague-Dawley rat colonocytes. Gut 1997; 40: 400-405. (Pubitemid 27145656)
43. Gibson GR, Macfarlane GT, Cummings JH. Sulfate reducing bacteria and hydrogen metabolism in the human large-intestine. Gut 1993; 34: 437-439. (Pubitemid 23093480)
44. Levine J, Ellis CJ, Furne JK et al. Fecal hydrogen sulfide production in ulcerative colitis. Am J Gastroenterol 1998; 93: 83-87. (Pubitemid 29065520)
45. Lindsay JO, Whelan K, Stagg AJ et al. Clinical, microbiological, and immuno logical effects of fructo-oligosaccharide in patients with Crohn's disease. Gut 2006; 55: 348-355. (Pubitemid 43268272)
46. De Preter V, Vanhoutte T, Huys G et al. Effects of Lactobacillus casei Shirota, Bifidobacterium breve, and oligofructose-enriched inulin on colonic nitrogen-protein metabolism in healthy humans. Am J Physiol Gastrointest Liver Physiol 2007; 292: G358-G368. (Pubitemid 46090279)
47. Hafer A, Kramer S, Duncker S et al. Effect of oral lactulose on clinical and immunohistochemical parameters in patients with inflammatory bowel disease: a pilot study. BMC Gastroenterol 2007; 7: 36.